- |||||||||| prasinezumab (RG7935) / Roche
Clinical, Journal: Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. (Pubmed Central) - Apr 22, 2024 This exploratory analysis suggests that, in a trial of 1-year duration, prasinezumab might reduce motor progression to a greater extent in individuals with more rapidly progressing Parkinson's disease. However, because this was a post hoc analysis, additional randomized clinical trials are needed to validate these findings.
- |||||||||| cinpanemab (BIIB054) / Biogen, prasinezumab (RG7935) / Roche, BAN0805 / BioArctic
Journal, Gene Signature: The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson's Disease. (Pubmed Central) - Dec 27, 2023 Therapeutic drugs that target SNCA include ABBV-0805, Prasinezumab, Cinpanemab, and Gardenin A. The results of this study suggest that cellular DEF-MDRGs might play an important role in PD. AR, ISCU, SNCA, and PDK4 have the potential to be specific biomarkers for the early diagnosis of PD.
- |||||||||| Review, Journal: Single-neuron neurodegeneration as a degenerative model for Parkinson's disease. (Pubmed Central) - Sep 18, 2023
In conclusion, based on the hypothesis that the neurodegenerative process of idiopathic Parkinson's disease corresponds to a single-neuron neurodegeneration model, we must search for molecules that increase the expression of the neuroprotective enzymes DT-diaphorase and glutathione transferase M2-2. It has been observed that the activation of the Kelch-like ECH-associated protein 1/nuclear factor (erythroid-derived 2)-like 2 pathway is associated with the transcriptional activation of the DT-diaphorase and glutathione transferase genes.
- |||||||||| prasinezumab (RG7935) / Roche
PASADENA 1-year open-label extension () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1439; P2 It has been observed that the activation of the Kelch-like ECH-associated protein 1/nuclear factor (erythroid-derived 2)-like 2 pathway is associated with the transcriptional activation of the DT-diaphorase and glutathione transferase genes. Objective: To describe the results of PASADENA 1-year open-label extension (OLE).; Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential to slow disease progression in Parkinson
- |||||||||| prasinezumab (RG7935) / Roche
Proof-of-concept clinical trial: Prevent cognitive decline in GBA-associated Parkinson () - Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1370; Based on these results, we suggest that it is the heavy cerebral ?-synuclein deposition that is causally linked to the accelerated progression with cognitive decline in PD.; We will conduct a proof-of-concept multicenter, international, randomized, double-blind, placebo-controlled clinical trial to investigate the efficacy of the monoclonal anti-?-synuclein antibody Prasinezumab (F... This is the first proof-of-concept clinical trial in PD addressing cognitive decline with a modifying agent based on a clear biological stratification and applied in a clearly defined prodromal phase preceding dementia to overcome the big challenge in modifying treatments of being
- |||||||||| #WPD2023 Parkinson’s Disease Emerging therapies such as CB101, Neural microtissues, NBTX 001, MEDI1341, Lu AF28996, KDT 3594, Prasinezumab, P2B001, DNL 151, Tavapadon are expected to have a significant impact on the PD market in the coming years @Medgadget https://t.co/huWF94ybh0 (Twitter) - Apr 10, 2023
- |||||||||| prasinezumab (RG7935) / Roche
A New View on Quantification of Disease Modification: Two Case Studies from Parkinson () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_497; Results from ADAGIO and PASADENA are inconclusive, due to differences in results across doses or outcomes. Regardless, estimation of time delays by methods such as the progression model for repeated measures could be helpful in quantifying disease-modifying aspects of treatments.
- |||||||||| prasinezumab (RG7935) / Roche, mesdopetam (IRL790) / Ipsen, tavapadon (CVL-751) / Cerevel Therap
NEW INSIGHT IN THE TREATMENT OF PARKINSONS DISEASE (ONSITE - HALL F1+F2+F3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_877; The PASADENA study tested prasinezumab and despite the primary end-point was not met positive signals were seen...The ORCHESTRA study with UCB0059, an oral Asyn antibody is also ongoing...A new dopamine agonist, tavapadon. Two different studies on dyskinesia are ongoing with a combination of buspirone and zolmitriptan and another with mesdopetam.
- |||||||||| prasinezumab (RG7935) / Roche
Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies (Poster Station: GPT 12) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1039; P2 We demonstrated that C-terminal/C-terminal tandem peptide-based vaccine candidates provide superior attributes to both single-peptide vaccines and other tandem peptide vaccines we investigated in all assays: α-syn titers, pathological α-syn staining in human PD brains, and inhibition of α-syn aggregate internalization into a neuronal cell line. These preclinical data support clinical development of multi-peptide vaccines for the potential treatment and prevention of PD and other synucleinopathies.
- |||||||||| prasinezumab (RG7935) / Roche
Estimating the Meaningful Within-Patient Change Threshold for the MDS-UPDRS Part III (Poster Station: 16) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_872; P2, P2b These findings indicate that a 5-point increase on MDS-UPDRS Part III can be used as a threshold for meaningful worsening of motor signs. This supports the use of time-to-5-point increase on MDS-UPDRS Part III as the primary endpoint for the Phase IIb PADOVA study, an ongoing randomised, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in early-stage PD (NCT04777331).
- |||||||||| prasinezumab (RG7935) / Roche
Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III (Poster Station: GPT 6) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_780; Progression in motor signs was larger under hypothetical compared with treatment policy strategy, suggesting a masking effect of symptomatic therapy. The consistent results under either estimand strategy suggest that a TTE analysis may mitigate the potential masking effect of symptomatic therapy on MDS-UPDRS Part III in PD.
- |||||||||| prasinezumab (RG7935) / Roche
Journal: Trial of Prasinezumab in Early-Stage Parkinson's Disease. (Pubmed Central) - Aug 11, 2022 P2 Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; PASADENA ClinicalTrials.gov number, NCT03100149.).
- |||||||||| prasinezumab (RG7935) / Roche
ESTIMATING THE MEANINGFUL WITHIN-PATIENT CHANGE THRESHOLD FOR THE MDS-UPDRS PART III () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1726; P2, P2b These findings indicate that a 5-point increase on MDS-UPDRS Part III can be used as a threshold for meaningful worsening of motor signs. This supports the use of time-to-5-point increase on MDS-UPDRS Part III as the primary endpoint for the Phase IIb PADOVA study, an ongoing randomised, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in ePD (NCT04777331).
- |||||||||| prasinezumab (RG7935) / Roche
Estimating the meaningful within-patient change threshold for the MDS-UPDRS Part III ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1807; P2, P2b These findings indicate that a 5-point increase on MDS-UPDRS Part III can be used as a threshold for meaningful worsening of motor signs. This supports the use of time-to-5-point increase on MDS-UPDRS Part III as the primary endpoint for the Phase IIb PADOVA study, an ongoing randomised, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in ePD (NCT04777331).
- |||||||||| cinpanemab (BIIB054) / Biogen, prasinezumab (RG7935) / Roche, MEDI1341 / AstraZeneca, Takeda
Clinical, Journal: Immunotherapies for Parkinson's disease: Progression of Clinical Development. (Pubmed Central) - Feb 19, 2022 This approach shows some positive outcomes on the efficacy in removing the aggregated species of alpha-synuclein, which is believed to be one of the causes of Parkinson's disease. In this review, an overview of how alpha-synuclein contributes to Parkinson's disease and the effects of a few new immunotherapeutic treatments, including BIIB054 (cinpanemab), MEDI1341, AFFITOPE and PRX002 (prasinezumab) that are currently under clinical development, will be discussed.
- |||||||||| TREATMENT OF PARKINSON’S DISEASE: WHAT ABOUT THE NEXT FUTURE (ONSITE: 112) - Dec 17, 2021 - Abstract #ADPD2022ADPD_279;
The ORCHESTRA study with UCB0059, an oral Asyn antibody is also recruiting...Two molecules are in clinical trials for GBA mutation, ambroxol and venglustat and one for patients with LRKK2 mutation, DNL151...Moreover to achive a more contnuos delivery of drug two subcutaneous preparation of levodopa are in clinical trials and olso an otal micropump able to deliver levodopa continuously. A new dopamine agonist, tavapadon and two drugs for dyskinesia are in clinical trial too.
|